Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Eur Urol. 2016 Dec 12;71(6):874–882. doi: 10.1016/j.eururo.2016.11.024

Fig. 3.

Fig. 3

Nuclear-specific AR-V7 localization improves prognostication of overall survival (OS) for patients on ARSi therapy. OS is shown for patient samples stratified by pre-ARSi AR-V7 status (n = 128) determined according to (A) nuclear-specific localization and (B) nuclear-agnostic localization and stratified by pre-taxane AR-V7 status (n = 63) determined according to (C) nuclear-specific localization and (D) nuclear-agnostic localization. ARSi = androgen receptor signaling inhibitor.